Cabaletta Bio, Inc.
CABA
$1.59
-$0.03-1.85%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 20.67% | 33.59% | 39.40% | 38.41% | 67.41% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 51.61% | 32.48% | 45.96% | 77.02% | 90.55% |
| Operating Income | -51.61% | -32.48% | -45.96% | -77.02% | -90.55% |
| Income Before Tax | -63.50% | -43.50% | -56.02% | -86.22% | -90.53% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -63.50% | -43.50% | -56.02% | -86.22% | -90.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -63.50% | -43.50% | -56.02% | -86.22% | -90.53% |
| EBIT | -51.61% | -32.48% | -45.96% | -77.02% | -90.55% |
| EBITDA | -52.21% | -32.61% | -46.06% | -78.14% | -92.35% |
| EPS Basic | -30.65% | -39.43% | -41.30% | -65.49% | -50.95% |
| Normalized Basic EPS | -30.64% | -39.43% | -41.32% | -65.53% | -50.97% |
| EPS Diluted | -30.23% | -38.88% | -41.30% | -65.73% | -51.35% |
| Normalized Diluted EPS | -30.64% | -39.43% | -41.32% | -65.53% | -50.97% |
| Average Basic Shares Outstanding | 25.14% | 2.92% | 10.41% | 12.53% | 26.22% |
| Average Diluted Shares Outstanding | 25.14% | 2.92% | 10.41% | 12.53% | 26.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |